Search
Parents interpreted pivotal vaccine-related events in the community as requiring them to take personal responsibility for vaccine decisions
New interventions to improve both education and communication on childhood and maternal vaccines may reduce vaccine hesitancy for all mothers in pregnancy
To assess the relative effectiveness of topical versus systemic antibiotics for people with chronic suppurative otitis media
For pathogens such as Staph. A and Streptococcus P., some hosts may carry the pathogen and transmit it to others, yet display no symptoms themselves.
We therefore speculate that removal of wP from the vaccine schedule contributed to the observed rise in IgE-mediated food allergy among Australian infants
To determine the contribution of RSV to the subsequent development of severe asthma in different subgroups of children at risk of severe RSV disease.
To develop consensus on the priorities for multi-centre, inpatient general paediatrics research in Australia and New Zealand.
Clinical trial designs are typically narrowly focused on error control in hypothesis testing, but this approach is inadequate in many contexts, particularly when a decision maker intends to, or must, consider multiple relevant clinical and health economic outcomes under uncertainty. Value-of-information (VoI) metrics can be used to estimate the monetary value of data collection to the decision maker.
BK polyomavirus (BKPyV) is a common opportunistic infection in kidney transplant recipients, typically reactivating in the context of immunosuppression. Although asymptomatic in immunocompetent individuals, reactivation in transplant recipients can cause BKPyV-associated nephropathy (BKPyVAN), a leading cause of graft dysfunction and loss. BKPyV viremia affects approximately 10%-15% of transplant recipients, and once BKPyVAN is established, the risk of graft failure can exceed 50%.
Australia's active vaccine safety surveillance system AusVaxSafety monitors a number of vaccines, including Arexvy, by reporting on solicited adverse events following immunisation (AEFI) through an online survey sent to vaccinees 3 days post-vaccination as previously described.3 Here we report on survey responses from adults aged ≥60 years receiving Arexvy at primary healthcare practices or pharmacies, who responded to the survey by day 7 post-vaccination.